Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
基本信息
- 批准号:10185766
- 负责人:
- 金额:$ 60.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-25 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAnti-Bacterial AgentsAntibody ResponseAryl Hydrocarbon ReceptorAutomobile DrivingBacteriaBacterial AntibodiesBile AcidsCell Differentiation processCellsChildClimactericCytoprotectionDevelopmentDiagnosisDietDietary SupplementationDiseaseDisease OutcomeEnvironmental Risk FactorEpidemicEpithelial CellsExhibitsFailureFoodFood HypersensitivityHuman MilkIgEImmuneImmune ToleranceImmune systemImmunoglobulin AImmunologicsIndividualInfantInterventionLicensingLifeLife StyleLipid ALong-Term EffectsMediatingMetabolismModernizationMolecularMucous MembraneMusOralPathogenesisPathogenicityPathway interactionsPlayPopulationPrevalenceProcessProductionPublic HealthReactionRegulationRegulatory T-LymphocyteRoleSolidSupplementationTLR4 geneTh2 CellsTherapeutic InterventionToll-like receptorsTryptophanWeaninganti-IgEaryl hydrocarbon receptor ligandbile acid metabolismcombinatorialcommensal bacteriadysbiosiseffective therapyfood allergenfood antigengut bacteriagut dysbiosisgut microbiomegut microbiotahuman subjectimmunoregulationinsightmicrobialmicrobiotanoveloral tolerancepreventresistinresponse
项目摘要
ABSTRACT
Food allergy (FA) has become a public health concern, affecting a sizeable segment of the population. Despite
the alarming increase in its prevalence, efforts to contain the FA epidemic have been stymied by the limited
understanding of disease pathogenesis, especially the role in this process of early life gut dysbiosis. In that
regard, our studies have established a critical role for immunomodulatory Clostridiales and Bacteroidales species
in enforcing immune tolerance to FA by inducing the differentiation of RORgt+ Treg cells, which act to suppress
FA. Early life expansion of RORgt+ Treg cells is induced by the bloom in Clostridiales and Bacteroidales species
during weaning from maternal milk to solid food. This expansion is counter-regulated by resistin-like molecule
beta (RELMb), which is elevated in FA subjects and mice. Accordingly, the focus of this proposal is to elucidate
the mechanisms by which early life dysbiosis promotes FA and its long-term implications in terms of disease
persistence and response to microbial therapy. We hypothesize that the microbial and immunological changes
ushered by weaning early in life provide a window of opportunity for tolerance induction to solid food in a process
regulated by RELMb, whose dysregulation by dysbiosis promotes FA (Aim 1). We also hypothesize that the
ineffective differentiation of RORgt+ Treg cell populations and the reciprocal emergence of Th2 cell-like Treg
cells, an imbalance we have identified to play a fundamental role in FA, acts to promote disease pathogenesis
by licensing IgE anti-food and anti-bacterial antibody responses (Aim 2). Finally, we hypothesize that products
and metabolites of individual immunomodulatory bacterial strains, including Toll-like receptors activators, aryl
hydrocarbon receptor ligands and secondary bile acids, act to enforce oral tolerance in FA by promoting RORgt+
Treg cell differentiation (Aim 3). The proposed studies will provide fundamental new insights relevant to the
pathogenesis of FA and offers novel opportunities in early life disease intervention and therapy.
摘要
食物过敏(FA)已成为一个公共卫生问题,影响了相当一部分人口。尽管
由于其流行率的惊人增长,控制FA流行的努力受到了有限的
了解疾病的发病机制,特别是在这一过程中的作用,早期生活肠道生态失调。在这
关于这一点,我们的研究已经确定了免疫调节梭菌目和拟杆菌目物种的关键作用
通过诱导RORgt+ Treg细胞的分化来加强对FA的免疫耐受,
FA. RORgt+ Treg细胞的早期生命扩增由梭菌目和拟杆菌目物种中的水华诱导
从母乳到固体食物的断奶过程中。这种扩张是由抵抗素样分子反调节的
β(α Mb),在FA受试者和小鼠中升高。因此,本提案的重点是阐明
早期生活生态失调促进FA的机制及其对疾病的长期影响
持久性和对微生物疗法的反应。我们假设微生物和免疫学变化
在生命的早期断奶为在一个过程中诱导对固体食物的耐受性提供了一个机会窗口
调节,其失调的生态失调促进FA(目的1)。我们还假设,
RORgt+ Treg细胞群的无效分化和Th2细胞样Treg的相互出现
细胞的不平衡,我们已经确定在FA中发挥重要作用,促进疾病的发病机制
通过许可IgE抗食物和抗细菌抗体反应(目标2)。最后,我们假设产品
和各个免疫调节细菌菌株的代谢物,包括Toll样受体激活剂、芳基
碳氢化合物受体配体和次级胆汁酸,通过促进RORgt+,
Treg细胞分化(Aim 3)。拟议的研究将提供与以下方面有关的基本新见解:
FA的发病机制,并提供了新的机会,在早期生活疾病的干预和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Talal Amine Chatila其他文献
Talal Amine Chatila的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Talal Amine Chatila', 18)}}的其他基金
Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
- 批准号:
10549764 - 财政年份:2021
- 资助金额:
$ 60.16万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10210940 - 财政年份:2021
- 资助金额:
$ 60.16万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10592358 - 财政年份:2021
- 资助金额:
$ 60.16万 - 项目类别:
Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
- 批准号:
10359843 - 财政年份:2021
- 资助金额:
$ 60.16万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10392449 - 财政年份:2021
- 资助金额:
$ 60.16万 - 项目类别:
Genetic and Epigenetic Programming of Allergic Airway Inflammation
过敏性气道炎症的遗传和表观遗传编程
- 批准号:
10169796 - 财政年份:2020
- 资助金额:
$ 60.16万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
10592379 - 财政年份:2019
- 资助金额:
$ 60.16万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
10386768 - 财政年份:2019
- 资助金额:
$ 60.16万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
9912720 - 财政年份:2019
- 资助金额:
$ 60.16万 - 项目类别:
Mechanisms of Combined Immunodeficiency due to DOCK8 Deficiency
DOCK8 缺陷引起的联合免疫缺陷的机制
- 批准号:
10238058 - 财政年份:2018
- 资助金额:
$ 60.16万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 60.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 60.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 60.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




